NovaDel Pharma to Begin Trading on American Stock Exchange Tomorrow FLEMINGTON, N.J., May 10 /PRNewswire-FirstCall/ -- NovaDel Pharma Inc. (BULLETIN BOARD: NVDL) today announced that its...
NovaDel Pharma at Rodman & Renshaw TechVest Global Conference May 12 FLEMINGTON, N.J., MAY 3 /PRNewswire-FirstCall/ -- NovaDel Pharma, Inc. (BULLETIN BOARD: NVDL) , a leading formulator of...
NovaDel Pharma's Third Foreign Patent Issued FLEMINGTON, N.J., April 22 /PRNewswire-FirstCall/ -- NovaDel Pharma Inc. (BULLETIN BOARD: NVDL) said it was awarded Greek Patent No.GR0904055...
NovaDel CEO Interviews on Wall Street Reporter First FDA Approval Filing to Occur Within Next Two Months; Five Tier One Drugs Entering Proof of Concept Studies FLEMINGTON, N.J., April 19...
NovaDel CEO to Be Interviewed Tomorrow by Wall St. Reporter FEMINGTON, N.J., April 15 /PRNewswire-FirstCall/ -- Gary Shangold, MD, chief executive officer of NovaDel Pharma, Inc. (BULLETIN...
NovaDel Announces Update on Experimental Lingual Spray Drug Will Be Presented at Anesthesia Meeting FLEMINGTON, N.J., April 14 /PRNewswire-FirstCall/ -- NovaDel Pharma, Inc. (BULLETIN BOARD:...
NovaDel Reports First Quarter 2004 Progress FLEMINGTON, N.J., Apr. 7 /PRNewswire-FirstCall/ -- NovaDel Pharma Inc. (BULLETIN BOARD: NVDL) reported substantial progress in product development...
NovaDel Names Robert G. Savage, Former Worldwide Head of Johnson & Johnson's Pharmaceutical Group, to Board FLEMINGTON, N.J., March 1 /PRNewswire-FirstCall/ -- NovaDel Pharma Inc. (BULLETIN...
NovaDel Raises $14 Million in Private Offering New Funding Will Accelerate Human Feasibility Studies of Four Top-Selling Drugs; First NDA Filing Scheduled for Q2-3 FLEMINGTON, N.J., Jan. 12...
NovaDel's Nitroglycerin Lingual Spray Achieves Important Safety and Efficacy Milestones In Randomized, Double-Blind Study FLEMINGTON, N.J., Oct. 27 /PRNewswire-FirstCall/ -- NovaDel Pharma Inc...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -2.44 | -2.93905083113 | 83.02 | 84.56 | 71.41 | 17012679 | 79.15130029 | SP |
4 | 3.9 | 5.08607198748 | 76.68 | 85.65 | 67.07 | 15513844 | 77.81476089 | SP |
12 | 19.91 | 32.8168781935 | 60.67 | 85.65 | 41.08 | 19148470 | 64.66185434 | SP |
26 | 38.52 | 91.5834522111 | 42.06 | 91.625 | 34.28 | 21632851 | 63.64736917 | SP |
52 | 63.44852161 | 370.362207893 | 17.13147839 | 91.625 | 13.92942632 | 14115924 | 57.86800099 | SP |
156 | 76.1984199 | 1739.06257927 | 4.3815801 | 91.625 | 2.95186885 | 7483105 | 56.91709616 | SP |
260 | 76.1984199 | 1739.06257927 | 4.3815801 | 91.625 | 2.95186885 | 7483105 | 56.91709616 | SP |
Aucune Discussion Trouvée |
Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales